CClinicalTrials.gg
Status unknownNCT03344133Updated Nov 17, 2017

Effect of Exercise Programme on Gut Microbiota, CVD Risk Factors and Appetite Regulation in Overweight Women

An interventional study of Exercise in Overweight and Obesity, sponsored by University of Glasgow. Status unknown at 1 site in United Kingdom. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by University of Glasgow · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Evidence suggests that gut microbiota contributes to the development of atherosclerosis and therefore CVDs. Exercise has been extensively reported to be protective against CVDs due to modification of body fatness, metabolic risk factors and cardio-respiratory fitness. It remains unclear whether impact of exercise on CVD risk can be at least in part explained by changes in the microbiota. It also remains to be investigated whether modification of appetite and appetite hormones due to participation in exercise are related to changes in the gut microbiota composition. Therefore, this study will be conducted in overweight, healthy, sedentary women and will investigate the effect of a 4-week moderate intensity exercise programme on gut microbiota composition and metabolic activity, plasma concentrations of fasting and postprandial lipids, glucose, insulin and inflammatory markers, fasting and postprandial gut appetite hormones, subjective appetite measures and cardio-respiratory fitness.

Read the detailed description

Study Design: This is a randomized controlled study with a parallel design. Healthy, sedentary females aged between 18-45 years old will be recruited by means of an advertisement leaflet and word of mouth. Eligible participants will be enrolled in the study and will be randomly allocated to either exercise intervention (EX) or control (C) groups. The EX group will participate in a 4-week exercise intervention and the C group will be asked to continue with habitual life style for 4 weeks. Before and after 4 weeks of the intervention, participants from both groups will be asked to conduct a submaximal exercise test and a 7-hour experimental trial during which blood samples will be collected and metabolic rate will measured before and after consumption of standardized breakfast and lunch. Prior to the first 7-hour trial, participants will be asked to record diet for 3 days and replicate this diet prior to the second 7-hour trial. During these 3 days participants will provide fresh stool samples. Participants allocated to control group will have the option to participate in exercise intervention. A subset of the participants will repeat a 7-hour experimental trial and provide fresh stool and urine sample after 7 days of detraining.

Methods:

Preliminary Health Check: Participants will undertake a health screening questionnaire on the day of recruitment. Participants will also need to fill in Physical Activity Readiness Questionnaire (PARQ). Only participants who answered "no" to all questions in PARQ will conduct the submaximal exercise test.

Anthropometry: All participants will have height, weight and waist circumference measured at baseline and 4 weeks after the intervention.

7-hour Experimental Trial: Participants will attend the metabolic suite (New Lister Building, Glasgow Royal infirmary) in a fasted state at approximately 9.00 am. Participants will be instructed to lie supine on the couch, with the head resting on the pillow provided. Resting metabolic rate will be measured for 20 minutes and fasting blood sample will be obtained. A breakfast meal will be consumed immediately after the fasting sample and a lunch meal after 4 hours. Blood samples will be taken throughout a cannula hourly after breakfast and lunch consumption. Following each blood sample, metabolic rate will be measured for the duration of 20 minutes. Prior each blood sample, participants will fill in appetite questionnaires. Blood samples will be analysed for plasma lipids, glucose, insulin, inflammatory markers and gut appetite hormones using standard existing procedures.

Feacal sample collection \& analysis: A disposable stool sample collection kit will be provided prior to the 7-hour trial day. Once collected, the container is sealed and placed in a larger sealable bag with a reducing sachet to remove oxygen and maintain anaerobic bacteria. Stool samples will be measured for changes in gut microbiota based on 16S rRNA amplicon sequencing, bacterial functional capacity and targeted bacterial metabolites (short chain fatty acids, sulphide, ammonia).

Exercise Training Programme: Exercise training will consist of 4 weekly sessions of endurance type exercise (cycling and running) lasting for 30, 40, 50, 60 minutes in the week 1, 2, 3 and 4 respectively. The time and day of each training trial will be agreed between the investigator and the participant and will be based around the participant's availability. All exercise sessions will be supervised by a researcher.

Submaximal Exercise Test: Participants will exercise on treadmill at gradually increasing intensities until 85% of maximal heart rate. During the last minute of each of the intensities heart rate will be measured and expired air will be collected by Douglas bag technique and analysed for oxygen consumption and carbon dioxide production. Relation between heart rate and rate of oxygen consumption will be used to predict maximal oxygen consumption, a marker of cardio-respiratory fitness.

02

Conditions studied

  • Overweight and Obesity

Browse trials for

Keywords

  • Obesity
  • Exercise
  • CVD risk factors
  • Appetite Regulation
  • Gut Microbiota
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy, sedentary females, BMI>25 kg/m2, on a stable body weight for the last 3 months

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic illness, use of antibiotics the past 3 months, smoking
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Exercise

    4-week moderate intensity exercise programme

    Behavioral: Exercise

  • No intervention
    Control

    4 weeks of habitual life style

Interventions

  • BehavioralExercise

    4-week moderate intensity exercise programme

05

What researchers measure

Primary outcomes

  1. Gut microbiota composition

    Changes in the gut microbiota composition measured by 16S rRNA amplicon sequencing.

    Time frame: 12 months

Secondary outcomes

  1. Interleukin-6 (IL-6)

    Changes in fasting and postprandial interleukin-6 pre- and post-interventions measured by Human IL-6 ELISA Ready-Set-Go (Affymetrix, eBioscience)

    Time frame: 3 months

  2. Glucose

    Changes in fasting glucose pre- and post-interventions measured by Randox Glucose

    Time frame: 3 months

  3. Triglycerides

    Changes in fasting and postprandial triglycerides pre- and post-interventions measured by Randox Triglycerides

    Time frame: 3 months

  4. Insulin

    Changes in fasting insulin pre- and post-interventions measured by Mercodia Insulin ELISA

    Time frame: 3 months

  5. Peptide YY (PYY)

    Changes in fasting and postprandial peptide YY pre- and post-interventions measured by Human PYY (Total) ELISA (Merc Millipore)

    Time frame: 12 months

  6. Glucagon-like peptide-1 (GLP-1)

    Changes in fasting and postprandial glucagon-like peptide-1 pre- and post-interventions measured by GLP-1 Total ELISA (Merc Millipore)

    Time frame: 12 months

  7. Subjective appetite

    Changes in subjective appetite (hunger, satiety, fullness, prospective food consumption, desire to eat) pre- and post-interventions measured by Visual Analogue Scales (VAS) where respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points (minimum score is 0 and maximum score is 100)

    Time frame: 12 months

  8. Faecal short-chain fatty acids

    Changes in concentrations of feacal short-chain fatty acids pre- and post-interventions measured by TRACE 2000 Gas Chromatography (ThermoQuest Ltd)

    Time frame: 12 months

  9. Faecal pH

    Changes in feacal pH between pre- and post-intervention measured by Hanna HI 98140

    Time frame: 1 month

  10. Body weight

    Differences in body weight (kilograms) between pre- and post-intervention measured by TANITA scales (TBF-300)

    Time frame: 1 month

  11. Height

    Height (meters) measured by stadiometer, a vertical ruler with a sliding horizontal paddle which is adjusted to rest on the top of the head

    Time frame: 1 month

  12. Body fat (kilograms)

    Differences in body fat expressed in kilograms between pre- and post-intervention measured by TANITA scales (TBF-300)

    Time frame: 1 month

  13. Body fat (% percentage)

    Differences in body fat expressed as percentage (%) (proportion of fat to the total body weight) between pre- and post-intervention measured by TANITA scales (TBF-300)

    Time frame: 1 month

  14. Body Mass Index (BMI)

    Differences in body mass index (weight and height will be combined to report BMI in kg/m\^2) between pre- and post-intervention measured by TANITA scales (TBF-300)

    Time frame: 1 month

  15. Dietary Intake

    Energy intake and macro nutrient intake using WinDiets software based on food composition tables

    Time frame: 6 months

  16. Maximum Oxygen Consumption

    Maximum Oxygen Consumption (ml/kg/min) measured before and after the interventions by Servomex Gas Analyser

    Time frame: 2 weeks

  17. Energy substrate oxidation

    Fat and carbohydrate oxidation in the fasted and postprandial state measured before and after the interventions using indirect calorimetry (Oxycon Pro)

    Time frame: 6 months

  18. Resting Metabolic Rate

    Resting metabolic rate was measured before and after the interventions (Oxycon Pro)

    Time frame: 2 month

06

Study locations

1 of 1 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03344133
Lead sponsor
University of Glasgow
Responsible party
Dr Konstantinos Gerasimidis (Senior Lecturer, University of Glasgow) — Principal investigator
First posted
Nov 17, 2017
Start date
Sep 16, 2015
Primary completion
Nov 30, 2017 (estimated)
Completion
Nov 30, 2017 (estimated)
Last update
Nov 17, 2017

Study contacts

Eleni Rizou, BSc MSc
Contact
e.rizou.1@research.gla.ac.uk
Konstantinos Gerasimidis, BSc MSc PhD
Contact
Konstantinos.Gerasimidis@glasgow.ac.uk
Konstantinos Gerasimidis, BSc MSc PhD
principal investigator · University of Glasgow

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion